Saturday, 14 July 2007 - Continuous improvement in kidney transplant survival has shifted attention to long-term outcomes, specifically to disorders linked to cardiovascular disease, physical capacity and quality of life....

by Vajdic CM,McDonald CM, McCredie MRE, van Leeuwen MT, Stewart JH, Law M,Chapman JR, Webster AC, Kaldor JM,Grulich AE

It is well known that immunosuppression following renal transplantation is associated with a marked increase...

Hyperhomocysteinemia and high IL-18 expression in renal allograft recipients may be independent markers of early atherosclerosis development

Steroid withdrawal in low risk kidney transplant recipients is safe and ameliorates many of the unwanted sides effects of steroid use

FTY720 is a novel immunomodulator investigated in de novo renal transplantation and other therapeutic areas including multiple sclerosis

FTY720, a sphingosine-1-phosphate receptor agonist, is the archeotype of a new class of immune modulators, which redirects lymphocytes from the peripheral blood into secondary lymphatic tissue

We performed a prospective randomized trial comparing sirolimus/ mycophenolate mofetil (MMF)/prednisone to cyclosporine/MMF/prednisone and selected induction therapy with basiliximab

Urinary tract infection (UTI), a major cause of morbidity in renal transplant recipients, has also been found to increase mortality

We compared the influence of induction therapy on 5-year patient and graft survival as well as on renal function in 100 kidney graft recipients